Results 111 to 120 of about 21,287 (236)
BackgroundThe short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to predict
H. Bennett +3 more
semanticscholar +1 more source
PKD1 variants are risk factors for autosomal dominant polycystic kidney disease (ADPKD). However, the detailed mechanisms by which PKD1 variants cause ADPKD remain unclear. Currently, there are no curative treatments for ADPKD.
Akihito Tanaka +14 more
doaj +1 more source
Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestry
Background: Causative mutations in the GANAB gene have been described in only 14 families, 9 diagnosed with late-onset Autosomal Dominant Polycystic Kidney Disease (ADPKD) and 5 with Autosomal Dominant Polycystic Liver Disease (ADPLD). Case: Diagnosis of
Alberici F. +17 more
core +1 more source
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, affecting approximately 1 in 1000 live births. It is characterised by multiple fluid-filled cysts in renal tubules.
Gul, Huseyin
core +1 more source
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disease, characterized by the progressive development of multiple kidney cysts, leading to a gradual decline in kidney function.
Abdul Hamid Borghol +5 more
doaj +1 more source
AIRP onlus partecipa al 1° Summit Europeo dedicato ai pazienti affetti da ADPKD
On Saturday the16th March 2019, AIRP participated at the 1st European ADPKD Patient Summit – a unique event designed to promote patient-centred care by providing an interactive forum for patients and experts to discuss ADPKD care, research and advocacy ...
Flavia Galletti, Franco Martini
doaj +1 more source
Clinical details of ADPKD patients and matched healthy subjects.
Clinical details of ADPKD patients and matched healthy subjects.
Marie C. Hogan (157476) +7 more
core +1 more source
Validation of the TEMPO 3:4 disease progression equations implemented within the ADPKD Outcomes Model. Trajectories of TKV progression were consistent with observed data from HALT-PKD Study A. Error bars depict 95% confidence intervals.
Albert Ong (4851901) +9 more
core +1 more source
Miwa Kaneko, Tetsu Akimoto, Daisuke Nagata Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, JapanCorrespondence: Tetsu Akimoto, Division of Nephrology, Department of Internal Medicine, Jichi Medical University ...
Kaneko M, Akimoto T, Nagata D
doaj
Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.
Research into metabolic reprogramming in cancer has become commonplace, yet this area of research has only recently come of age in nephrology. In light of the parallels between cancer and autosomal dominant polycystic kidney disease (ADPKD), the latter ...
J. Trott +11 more
semanticscholar +1 more source

